ArticleProstate international2022
Association of serum prostate-specific antigen (PSA) level and circulating tumor cell-based PSA mRNA in prostate cancer.
Article in Prostate international, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 15 citations in OpenAlex.
- Plasma circulating tumor deoxyribonucleic acid methylation enables noninvasive disease stratification beyond prostate-specific antigen in prostate cancer.Prostate international · 2026Article
- Article
- Integrating shear wave elastography and multiparametric MRI for accurate prostate cancer diagnosis.American journal of cancer research · 2025Article
- Emerging Multifunctional Carbon-Nanomaterial-Based Biosensors for Cancer Diagnosis.Small science · 2024Article
- Advances in Prostate Cancer Biomarkers and Probes.Cyborg and bionic systems (Washington, D.C.) · 2024Review
- Management of a localized prostatic adenocarcinoma despite the very high rate of PSA and the large tumor mass: Does PSA level indicate the stage of prostate cancer?Radiology case reports · 2023Article
- Autophagy, a critical element in the aging male reproductive disorders and prostate cancer: a therapeutic point of view.Reproductive biology and endocrinology : RB&E · 2023Review
- Screening and validation of novel serum panel of microRNA in stratification of prostate cancer.Prostate international · 2023Article
- Circulating cervical cancer biomarkers potentially useful in medical attention (Review).Molecular and clinical oncology · 2023Review
- Study on the Diagnostic Value of Contrast-Enhanced Ultrasound and Magnetic Resonance Imaging in Prostate Cancer.Evidence-based complementary and alternative medicine : eCAM · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate-specific antigen (PSA) is used for diagnosing prostate cancer, but does not reflect the characteristics of prostate cancer cells to allow assessment of cancer progression. PSA mRNA and circulating tumor cells (CTCs) could be potential biomarkers. However, the relationship between serum PSA levels and PSA mRNA in CTCs is unclear, and this study aimed to investigate this relationship.
methodsHealthy donors (HD,
resultsPSA mRNA expression in CTCs was observed in 30% (9/30) of patients with localized cancer, 60.0% (6/10) among patients with mHSPC, 65.3% (49/75) among patients with mCRPC, and 0% among patients with HD, indicating that the detection rate of PSA mRNA increased with cancer stage. PSA mRNA expression in CTCs also increased from localized to metastatic stages. PSA mRNA levels rapidly increased in the mHSPC and mCRPC stages. Interestingly, PSA mRNA expression in CTCs was not correlated with serum PSA levels at the localized stage (
conclusionCTC PSA mRNA has the potential to be used as a biomarker to complement serum PSA protein analysis or replace serum PSA in metastatic stages of prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.